Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTUITIVE SURGICAL INCISRG · Entity 2878 | Director | May 18, 2011 | May 19, 2011 |
| PULSE BIOSCIENCES, INC.PLSE · Entity 1151 | Director · 10% owner | June 11, 2026 | June 16, 2026 |
| Summit Therapeutics Inc.SMMT · Entity 3477 | Director · Co-Chief Executive Officer · 10% owner | June 12, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTUITIVE SURGICAL INC
Report date May 18, 2011 · Filed May 19, 2011
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,000 |
Reported balance
After 2011-05-18 transaction · row 1
1 source rowRow 1 · 2011-05-18 · Exercise / conversion · Acquired 1,000 · Balance 1,000 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.09 · Expires 2015-05-20 | Direct | 0 |
Reported balance
After 2011-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2011-05-18 · Exercise / conversion · Disposed 1,000 · Balance 0 F1: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant date.
PULSE BIOSCIENCES, INC.
Report date June 11, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.89 · Expires 2036-06-11 | Direct | 30,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.89 · Expires 2036-06-11 | Direct | 12,495 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 12,495 · Balance 12,495 F2: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026.
F2: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026.
Summit Therapeutics Inc.
Report date June 12, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 573,883,879 |
Reported balance
After 2026-06-12 transaction · row 1
1 source rowRow 1 · 2026-06-12 · Purchase · Acquired 3,810,000 · Balance 573,883,879 |
| Common StockSEC Table I · non-derivative | IndirectBy the Mahkam Zanganeh Revocable Trust, with the Spouse of Reporting Person as Trustee | 25,824,474 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 25,824,474 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectImmediate family member of Spouse | 76,680 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 76,680 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 31,000 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 31,000 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy the Shaun Zanganeh Irrevocable Trust, with the Spouse of Reporting Person as Trustee | 10,199,776 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 10,199,776 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Achaogen, Inc.
Report date March 18, 2019 · Filed March 20, 2019
Section 16 reporting ended · disclosed 2019-03-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 5,555,414 |
Ending reported balance
After 2019-03-20 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-03-18 · Sale · Disposed 271,879 · Balance 6,561,423 Row 2 · 2019-03-19 · Sale · Disposed 956,009 · Balance 5,605,414 Row 3 · 2019-03-20 · Sale · Disposed 50,000 · Balance 5,555,414 |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee Footnote | 30,000 |
Reported balance
Holding disclosure · report date 2019-03-18 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 30,000 F1: Shares held by Blaze-On Corporation, of which the Reporting Person is the sole officer and director. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee Footnote | 100,255 |
Reported balance
Holding disclosure · report date 2019-03-18 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 100,255 F2: Shares held by Robert W. Duggan Foundation, of which the Reporting Person is the President. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee Footnote | 72,170 |
Reported balance
Holding disclosure · report date 2019-03-18 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 72,170 F3: Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held by Blaze-On Corporation, of which the Reporting Person is the sole officer and director.
F2: Shares held by Robert W. Duggan Foundation, of which the Reporting Person is the President.
F3: Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2022 Filed Jun 10, 2022 23:00 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 81,025 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-22-006924 · duggan-form4_061022.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · footnote Disclosed balance after: 411,044 F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and the Prospectus Supplement and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $2.05 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $2.05. F3 · ownership.nature: Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 23:00 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 5,683,163 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-22-006924 · duggan-form4_061022.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,391,724 F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and the Prospectus Supplement and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $2.05 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $2.05. Read SEC document |
| May 23, 2022 Filed May 26, 2022 00:45 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | OtherCommon Stock | 21,135 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-064838 · tm2216975-1_4seq1.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,683,589 F1 · kind: The shares of Common Stock were collateral for a loan made by the Reporting Person to a third party, and were transferred to the Reporting Person in full satisfaction of the loan. F1 · price: The shares of Common Stock were collateral for a loan made by the Reporting Person to a third party, and were transferred to the Reporting Person in full satisfaction of the loan. Read SEC document |
| May 19, 2022 Filed May 24, 2022 00:51 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 110,467 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001104659-22-064001 · tm2216672-1_4seq1.xml · derivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,467 Underlying: Common Stock · 110,467 shares Expires 2032-05-19 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on August 19, 2022. Read SEC document |
| May 19, 2022 Filed May 24, 2022 00:51 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001104659-22-064001 · tm2216672-1_4seq1.xml · derivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-19 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on June 19, 2022. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:48 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 3,048,780 | $16.40 | $49,999,992.00 |
DisclosureSEC source: 0001209191-21-045022 · doc4.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,708,561 F1 · kind: Shares were acquired pursuant to the terms of that certain purchase agreement by and between the Reporting Person and the Issuer, of which consideration included the satisfaction of a loan from the Reporting Person to the Issuer. Read SEC document |
| May 20, 2021 Filed May 21, 2021 21:04 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 11,605 | $0.00 Strike: $18.69 | $0.00 |
DisclosureSEC source: 0001209191-21-035005 · doc4.xml · derivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,605 Underlying: Common Stock · 11,605 shares Expires 2031-05-20 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 20, 2021 Filed May 21, 2021 21:04 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $18.69 | $0.00 |
DisclosureSEC source: 0001209191-21-035005 · doc4.xml · derivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-20 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:39 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 11,365,921 | $5.24 | $59,557,426.04 |
DisclosureSEC source: 0000921895-21-001335 · form412566dug_05142021.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,662,454 F1 · shares: Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 02:11 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherWarrant (right to buy) · Derivative | 8,214 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0001209191-20-065607 · doc4.xml · derivative · entry 4 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 8,214 shares Expires 2025-06-15 F1 · ownership.nature: Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 02:11 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherWarrant (right to buy) · Derivative | 376,065 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0001209191-20-065607 · doc4.xml · derivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 376,065 shares Expires 2025-06-15 Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 02:11 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 8,214 | $7.01 | $57,580.14 |
DisclosureSEC source: 0001209191-20-065607 · doc4.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 330,019 F1 · ownership.nature: Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 02:11 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 376,065 | $7.01 | $2,636,215.65 |
DisclosureSEC source: 0001209191-20-065607 · doc4.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,659,781 Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 21:25 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 14,071,856 | $3.34 | $46,999,999.04 |
DisclosureSEC source: 0000921895-20-002868 · form412566001_11102020.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,296,533 F1 · shares: Represents the number of shares of Common Stock that the Reporting Person purchased in a private placement at a price of $3.34 per share pursuant to a Securities Purchase Agreement, dated October 2, 2020, by and between the Reporting Person and the Issuer (the "Purchase Agreement"). Pursuant to the Purchase Agreement, the Issuer directed the Reporting Person to purchase 14,071,856 shares of Common Stock. Read SEC document |
| October 02, 2020 Filed Oct 6, 2020 23:42 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantCommon Stock · Derivative | 9,730,539 | Not disclosed Strike: $3.34 | Not disclosed |
DisclosureSEC source: 0000921895-20-002547 · form412566002_10062020.xml · derivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,730,539 Underlying: Common Stock · 9,730,539 shares Expires not disclosed F1 · shares: Represents the minimum number of shares that the Reporting Person shall be obligated to purchase in a private placement pursuant to a Securities Purchase Agreement, dated October 2, 2020, by and between the Reporting Person and the Issuer (the "Purchase Agreement"). The Purchase Agreement affords the Issuer sole discretion to place up to 14,970,060 shares of Common Stock or as few as 9,730,539 shares of Common Stock to the Reporting Person. The shares are issuable at price of $3.34 per share of Common Stock in accordance with the terms of the Purchase Agreement. F1 · price: Represents the minimum number of shares that the Reporting Person shall be obligated to purchase in a private placement pursuant to a Securities Purchase Agreement, dated October 2, 2020, by and between the Reporting Person and the Issuer (the "Purchase Agreement"). The Purchase Agreement affords the Issuer sole discretion to place up to 14,970,060 shares of Common Stock or as few as 9,730,539 shares of Common Stock to the Reporting Person. The shares are issuable at price of $3.34 per share of Common Stock in accordance with the terms of the Purchase Agreement. F2 · derivative.exercise_date: The closing of the Purchase Agreement is anticipated to occur in approximately two weeks' time. F2 · derivative.expiration_date: The closing of the Purchase Agreement is anticipated to occur in approximately two weeks' time. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:03 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseWarrant (right to buy) · Derivative | 8,214 | Not disclosed Strike: $7.01 | Not disclosed |
DisclosureSEC source: 0001209191-20-037223 · doc4.xml · derivative · entry 4 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 8,214 Underlying: Common Stock · 8,214 shares Expires 2025-06-15 F1 · kind: The Reporting Person acquired the shares and warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering, as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F1 · price: The Reporting Person acquired the shares and warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering, as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · ownership.nature: Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:03 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseWarrant (right to buy) · Derivative | 376,065 | Not disclosed Strike: $7.01 | Not disclosed |
DisclosureSEC source: 0001209191-20-037223 · doc4.xml · derivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,065 Underlying: Common Stock · 376,065 shares Expires 2025-06-15 F1 · kind: The Reporting Person acquired the shares and warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering, as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F1 · price: The Reporting Person acquired the shares and warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering, as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:03 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 54,761 | $7.01 | $383,874.61 |
DisclosureSEC source: 0001209191-20-037223 · doc4.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 321,805 F1 · kind: The Reporting Person acquired the shares and warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering, as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · ownership.nature: Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:03 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 2,507,112 | $7.01 | $17,574,855.12 |
DisclosureSEC source: 0001209191-20-037223 · doc4.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,283,716 F1 · kind: The Reporting Person acquired the shares and warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering, as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. Read SEC document |
| May 18, 2020 Filed May 19, 2020 22:23 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 20,347 | $0.00 Strike: $10.66 | $0.00 |
DisclosureSEC source: 0001209191-20-030674 · doc4.xml · derivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,347 Underlying: Common Stock · 20,347 shares Expires 2030-05-18 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 18, 2020 Filed May 19, 2020 22:23 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $10.66 | $0.00 |
DisclosureSEC source: 0001209191-20-030674 · doc4.xml · derivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-18 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 16, 2019 Filed May 17, 2019 21:01 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 13,124 | $0.00 Strike: $13.03 | $0.00 |
DisclosureSEC source: 0001209191-19-031015 · doc4.xml · derivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,124 Underlying: Common Stock · 13,124 shares Expires 2029-05-16 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 16, 2019 Filed May 17, 2019 21:01 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $13.03 | $0.00 |
DisclosureSEC source: 0001209191-19-031015 · doc4.xml · derivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-05-16 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 20, 2019 Filed Mar 20, 2019 21:24 UTC | Achaogen, Inc. AKAO · Entity 158957 | SaleCommon Stock, par value $0.001 per share | 50,000 | $0.53 | $26,500.00 |
DisclosureSEC source: 0000921895-19-000842 · form406922005_03202019.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,555,414 Read SEC document |
| March 19, 2019 Filed Mar 20, 2019 21:24 UTC | Achaogen, Inc. AKAO · Entity 158957 | SaleCommon Stock, par value $0.001 per share | 956,009 | $0.53 | $506,684.77 |
DisclosureSEC source: 0000921895-19-000842 · form406922005_03202019.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,605,414 Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 21:24 UTC | Achaogen, Inc. AKAO · Entity 158957 | SaleCommon Stock, par value $0.001 per share | 271,879 | $0.56 | $152,252.24 |
DisclosureSEC source: 0000921895-19-000842 · form406922005_03202019.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,561,423 Read SEC document |
| March 13, 2019 Filed Mar 13, 2019 21:31 UTC | Achaogen, Inc. AKAO · Entity 158957 | SaleCommon Stock, par value $0.001 per share | 1,199,930 | $0.59 | $707,958.70 |
DisclosureSEC source: 0000921895-19-000731 · form406922005_03132019.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,833,302 Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 21:31 UTC | Achaogen, Inc. AKAO · Entity 158957 | SaleCommon Stock, par value $0.001 per share | 633,975 | $0.61 | $386,724.75 |
DisclosureSEC source: 0000921895-19-000731 · form406922005_03132019.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,033,232 Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 21:31 UTC | Achaogen, Inc. AKAO · Entity 158957 | SaleCommon Stock, par value $0.001 per share | 520,102 | $0.63 | $327,664.26 |
DisclosureSEC source: 0000921895-19-000731 · form406922005_03132019.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,667,207 Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:13 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 4,444 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001209191-19-003033 · doc4.xml · derivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,444 Underlying: Common Stock · 4,444 shares Expires 2029-01-07 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the date of the Issuer's Annual Meeting to be held in 2019, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 21:05 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 232,044 | $12.57 | $2,915,818.50 |
DisclosureSEC source: 0001209191-18-062920 · doc4.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 267,044 F1 · kind: The Reporting Person acquired the shares pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering, as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · ownership.nature: Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 21:05 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 2,914,182 | $12.57 | $36,619,028.18 |
DisclosureSEC source: 0001209191-18-062920 · doc4.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,776,604 F1 · kind: The Reporting Person acquired the shares pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering, as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 23:23 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 306,848 | $1.65 | $505,010.44 |
DisclosureSEC source: 0000921895-18-003283 · form406922005_12122018.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,187,309 Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 23:23 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 436,500 | $1.60 | $697,788.90 |
DisclosureSEC source: 0000921895-18-003283 · form406922005_12122018.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,880,461 Read SEC document |
| December 07, 2018 Filed Dec 11, 2018 22:44 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 22,431 | $1.40 | $31,394.43 |
DisclosureSEC source: 0000921895-18-003263 · form406922005_12112018.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,443,961 Read SEC document |
| November 27, 2018 Filed Nov 27, 2018 22:22 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 77,585 | $1.68 | $129,962.63 |
DisclosureSEC source: 0000921895-18-003165 · form406922005_11272018.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,421,530 Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 22:22 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 80,175 | $1.89 | $151,643.00 |
DisclosureSEC source: 0000921895-18-003165 · form406922005_11272018.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,343,945 Read SEC document |
| November 20, 2018 Filed Nov 23, 2018 18:45 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 231,495 | $1.93 | $446,947.40 |
DisclosureSEC source: 0001193805-18-001360 · e618071_4-akao.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,263,770 Read SEC document |
| November 19, 2018 Filed Nov 20, 2018 21:08 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 4,648 | $1.62 | $7,524.65 |
DisclosureSEC source: 0000921895-18-003124 · form406922005_11202018.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,032,275 Read SEC document |
| May 23, 2018 Filed May 24, 2018 22:35 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $15.27 | $0.00 |
DisclosureSEC source: 0001209191-18-033150 · doc4.xml · derivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-05-23 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 11, 2018 Filed May 16, 2018 00:07 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 21,353 | $23.16 | $494,535.48 |
DisclosureSEC source: 0001209191-18-030347 · doc4.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,862,422 Read SEC document |
| May 03, 2018 Filed May 7, 2018 21:54 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 100,255 | $11.43 | $1,146,315.67 |
DisclosureSEC source: 0001193805-18-000627 · e617976_4-akao.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 100,255 F2 · ownership.nature: Shares held by Robert W. Duggan Foundation, of which the Reporting Person is the President. Read SEC document |
| May 03, 2018 Filed May 7, 2018 21:54 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 30,000 | $11.54 | $346,338.00 |
DisclosureSEC source: 0001193805-18-000627 · e617976_4-akao.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 30,000 F1 · ownership.nature: Shares held by Blaze-On Corporation, of which the Reporting Person is the sole officer and director. Read SEC document |
| May 03, 2018 Filed May 7, 2018 21:54 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 846,625 | $11.31 | $9,579,477.21 |
DisclosureSEC source: 0001193805-18-000627 · e617976_4-akao.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,027,627 Read SEC document |
| April 27, 2018 Filed Apr 27, 2018 22:30 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 102,849 | $12.96 | $1,333,159.59 |
DisclosureSEC source: 0000921895-18-001492 · form406922005_04272018.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,181,002 Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 22:30 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 50,000 | $12.96 | $647,755.00 |
DisclosureSEC source: 0000921895-18-001492 · form406922005_04272018.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,078,153 Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 22:30 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 77,247 | $13.02 | $1,005,949.06 |
DisclosureSEC source: 0000921895-18-001492 · form406922005_04272018.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,028,153 Read SEC document |
| April 23, 2018 Filed Apr 23, 2018 22:50 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 132,487 | $13.07 | $1,730,969.15 |
DisclosureSEC source: 0000921895-18-001425 · form406922005_04232018.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,950,906 Read SEC document |
| April 20, 2018 Filed Apr 23, 2018 22:50 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 216,150 | $13.23 | $2,860,421.03 |
DisclosureSEC source: 0000921895-18-001425 · form406922005_04232018.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,818,419 Read SEC document |
| April 19, 2018 Filed Apr 23, 2018 22:50 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 119,700 | $12.76 | $1,527,264.27 |
DisclosureSEC source: 0000921895-18-001425 · form406922005_04232018.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,602,269 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.